🔍

SUVEN - Suven Life Scie.

📊 NSE: SUVEN 🏢 Miscellaneous 📅 Last Updated: 12/14/2025 13:59

📢 Recent Corporate Announcements

Suven Life Sciences Allots 3.17 Cr Shares to Promoters, Raising Rs 425.7 Crore

🟢 POSITIVE ⭐ 8/10

FUNDRAISE 📅 06 Mar 2026, 11:48 AM

Suven Life Sciences has successfully converted 3,17,68,764 warrants into equity shares, resulting in a significant capital infusion of Rs 425.7 crore. The shares were allotted to the promoter group entity, Jasti Property and Equity Holdings Private Limited, at an issue price of Rs 134 per share. This transaction increases the company's total paid-up equity capital from 23.19 crore shares to 26.37 crore shares. The receipt of 100% consideration from the promoters demonstrates strong internal confidence in the company's long-term value.

Allotment of 3,17,68,764 equity shares to the promoter group upon conversion of warrants.
Total capital infusion of Rs 425,70,14,376 received at an issue price of Rs 134 per share.
Paid-up equity share capital increased to 26,37,20,583 shares of Rs 1 each.
The allottee is Jasti Property and Equity Holdings Private Limited (Jasti Family Trust).
The board meeting for the allotment concluded within 20 minutes on March 6, 2026.

💡 The promoter's decision to infuse substantial capital at Rs 134 per share is a strong signal of commitment and confidence. Investors should monitor the company's utilization of these funds toward its R&D pipeline and clinical trials.

Suven Life Sciences Allots 3.17 Cr Equity Shares to Promoter; Raises Rs 425.7 Crore

🟢 POSITIVE ⭐ 8/10

FUNDRAISE 📅 06 Mar 2026, 11:37 AM

Suven Life Sciences has successfully converted 3,17,68,764 warrants into equity shares, allotting them to the promoter group entity, Jasti Family Trust. The transaction was executed at an issue price of Rs. 134 per share, resulting in a total fund infusion of Rs. 425.70 crore. This capital injection has increased the company's total paid-up equity share capital to 26.37 crore shares. The 100% receipt of consideration from the promoter highlights strong internal support for the company's long-term objectives.

Allotment of 3,17,68,764 equity shares at Rs. 134 per share (including Rs. 133 premium).
Total consideration received from the promoter group amounts to Rs. 425.70 crore.
The allotment was made to Jasti Property and Equity Holdings Private Limited (Jasti Family Trust).
Paid-up equity capital increased from 23,19,51,819 to 26,37,20,583 shares.
The board meeting for this allotment was concluded on March 6, 2026.

💡 The promoter's decision to exercise warrants at Rs. 134 suggests a bullish outlook on the company's valuation. Investors should maintain their positions while watching for updates on the utilization of these funds in clinical trials or R&D.

Suven Life Sciences Clarifies No Undisclosed Material Events Behind Recent Price Movement

🟡 NEUTRAL ⭐ 3/10

ROUTINE 📅 06 Feb 2026, 10:34 AM

Suven Life Sciences Limited has responded to a clarification request from the National Stock Exchange regarding recent significant movements in its stock price and trading volume. The company officially stated that it has no undisclosed material information or events that could impact the scrip's behavior. Management confirmed that all disclosures required under Regulation 30 of SEBI (LODR) Regulations, 2015, have been made. The company attributes the recent volatility to market speculation rather than any internal corporate developments.

Responded to NSE surveillance query dated February 5, 2026, regarding stock price volatility
Confirmed full compliance with SEBI (LODR) Regulations, 2015, regarding material disclosures
Stated no pending announcements or events exist that would affect price or volume behavior
Attributed recent price and volume fluctuations to general market speculation

💡 Investors should exercise caution as the company has confirmed no fundamental news is driving the recent price action. Avoid reacting to speculative rumors and wait for official corporate developments or earnings results.

Suven Life Sciences Raises ₹60 Crore via Warrant Conversion; Appoints New Company Secretary

🟢 POSITIVE ⭐ 7/10

FUNDRAISE 📅 29 Jan 2026, 01:32 PM

Suven Life Sciences has successfully raised ₹60 crore through the allotment of 44.77 lakh equity shares to 3P India Equity Fund entities. This allotment follows the conversion of fully paid warrants at an issue price of ₹134 per share, which is a significant premium over the face value. Consequently, the company's paid-up equity share capital has increased to 23.19 crore shares. Additionally, the company announced the appointment of Ms. Sangeetha Laxmi Kandari as the new Company Secretary and Compliance Officer, effective February 2, 2026, following the resignation of Mr. Shrenik Soni.

Allotted 44,77,612 equity shares at an issue price of ₹134 per share (₹1 face value + ₹133 premium)
Total capital raised through warrant conversion amounts to ₹60,00,00,008
Post-issue paid-up equity capital increased from 22,74,74,207 to 23,19,51,819 shares
Institutional investors 3P India Equity Fund 1 and 1M were the sole allottees in this conversion
Ms. Sangeetha Laxmi Kandari appointed as CS & Compliance Officer with over 9 years of experience

💡 Investors should view the ₹60 crore capital infusion from institutional funds as a positive sign of confidence in the company's valuation. Monitor the company's upcoming R&D updates to see how this capital is deployed for growth.

Suven Life Sciences Allots Shares Worth ₹60 Cr on Warrant Conversion & Appoints New CS

🟢 POSITIVE ⭐ 7/10

FUNDRAISE 📅 29 Jan 2026, 01:26 PM

Suven Life Sciences has approved the allotment of 44,77,612 equity shares following the conversion of fully paid warrants, raising approximately ₹60 crore. The shares were issued to 3P India Equity Fund entities at a price of ₹134 per share, increasing the total paid-up capital to 23.19 crore shares. Alongside this capital infusion, the company announced a transition in its secretarial department. Mr. Shrenik Soni has resigned as Company Secretary, and Ms. Sangeetha Laxmi Kandari, who brings over 9 years of experience, will take over the role effective February 2, 2026.

Allotted 44,77,612 equity shares at an issue price of ₹134 per share (₹1 face value + ₹133 premium)
Total consideration of ₹60,00,00,008 received from 3P India Equity Fund 1 and 3P India Equity Fund 1M
Post-issue subscribed and paid-up capital increased to ₹23,19,51,819
Mr. Shrenik Soni to step down as Company Secretary and Compliance Officer on January 30, 2026
Ms. Sangeetha Laxmi Kandari appointed as the new CS and Compliance Officer effective February 2, 2026

💡 Investors should view the ₹60 crore fundraise as a positive liquidity event for the company's R&D-heavy business model. The immediate appointment of a successor for the Compliance Officer role indicates stable corporate governance.

Suven Life Sciences Allots 44.77 Lakh Shares on Warrant Conversion, Raising Rs 60 Crore

🟢 POSITIVE ⭐ 7/10

FUNDRAISE 📅 29 Jan 2026, 01:14 PM

Suven Life Sciences has approved the allotment of 44,77,612 equity shares following the conversion of fully paid warrants. The shares were issued at a price of Rs. 134 per share, resulting in a total capital infusion of approximately Rs. 60 crore from non-promoter entities, specifically 3P India Equity Fund. This conversion increases the company's total paid-up equity share capital to 23.19 crore shares. Additionally, the company announced a change in its Key Managerial Personnel, with a new Company Secretary taking over in February 2026.

Allotment of 44,77,612 equity shares at an issue price of Rs. 134 per share
Total consideration received from allottees amounts to Rs. 60,00,00,008
Primary allottees are 3P India Equity Fund 1 and 3P India Equity Fund 1M
Post-issue paid-up capital increased to 23,19,51,819 shares from 22,74,74,207 shares
Appointment of Ms. Sangeetha Laxmi Kandari as CS & Compliance Officer effective Feb 02, 2026

💡 Investors should view the capital infusion of Rs. 60 crore as a positive sign of institutional interest from 3P India Equity Fund. Monitor the utilization of these funds toward the company's R&D and drug discovery pipeline.

Suven Life Sciences Allots 44.77 Lakh Shares on Warrant Conversion, Raises Rs 60 Crore

🟢 POSITIVE ⭐ 7/10

FUNDRAISE 📅 29 Jan 2026, 01:04 PM

Suven Life Sciences has successfully converted 44,77,612 warrants into equity shares, resulting in a capital infusion of approximately Rs 60 crore. The shares were allotted to 3P India Equity Fund entities at an issue price of Rs 134 per share, which includes a premium of Rs 133. This conversion has increased the company's total paid-up equity share capital to 23.19 crore shares. Alongside this fundraise, the company announced a transition in its compliance leadership, appointing Ms. Sangeetha Laxmi Kandari as the new Company Secretary.

Allotment of 44,77,612 equity shares at an issue price of Rs 134 per share
Total capital infusion of Rs 60,00,00,008 received from non-promoter entities 3P India Equity Fund
Post-issue paid-up equity capital increased to 23,19,51,819 shares from 22,74,74,207 shares
Appointment of Ms. Sangeetha Laxmi Kandari as Company Secretary & Compliance Officer effective February 02, 2026
Resignation of outgoing Company Secretary Mr. Shrenik Soni to pursue alternate career opportunities

💡 Investors should view the Rs 60 crore capital infusion as a positive for the company's liquidity and balance sheet strength. Monitor the company's upcoming R&D updates to see how this capital is deployed for growth.

Suven Life Sciences Submits SEBI Regulation 74(5) Compliance Certificate for Q3 FY26

🟡 NEUTRAL ⭐ 2/10

ROUTINE 📅 06 Jan 2026, 10:14 AM

Suven Life Sciences has filed its quarterly compliance certificate under Regulation 74(5) of SEBI (Depositories and Participants) Regulations, 2018. The certificate, issued by KFin Technologies Limited, confirms that the details of securities dematerialized or rematerialized during the quarter ended December 31, 2025, have been furnished to the stock exchanges. This is a standard administrative procedure to ensure that the company's share records are accurately maintained with depositories like NSDL and CDSL. The filing indicates the company is meeting its routine regulatory obligations on time.

Compliance certificate submitted for the quarter ended December 31, 2025.
Registrar and Transfer Agent (RTA) KFin Technologies Limited confirmed the processing of demat/remat requests.
Filing covers requirements under Regulation 74(5) of SEBI (Depositories and Participants) Regulations, 2018.
The certificate was issued by the RTA on January 01, 2026, and submitted to exchanges on January 06, 2026.

💡 This is a routine regulatory filing with no impact on the company's business operations or financial health. No action is required from investors.

Suven Life Sciences to Close Trading Window from Jan 1, 2026 for Q3 Results

🟡 NEUTRAL ⭐ 2/10

ROUTINE 📅 29 Dec 2025, 05:23 PM

Suven Life Sciences Limited has announced the closure of its trading window for all designated persons starting January 1, 2026. This action is taken in accordance with SEBI (Prohibition of Insider Trading) Regulations, 2015, ahead of the Q3 financial results for the period ending December 31, 2025. The window will remain shut until 48 hours after the financial results are officially declared to the public. This is a mandatory compliance step for all listed entities in India to prevent insider trading.

Trading window closure starts effective January 1, 2026
Closure pertains to the financial results for the quarter ending December 31, 2025
The window will reopen 48 hours after the results are disclosed to the stock exchanges
Restriction applies to all designated persons and their relatives as per the company's code of conduct

💡 This is a standard administrative procedure; investors should wait for the official announcement of the board meeting date to review the Q3 financial performance.

Suven Reaches 100% Enrollment in Ropanicant Phase-2b Trial 2 Months Ahead of Schedule

🟢 POSITIVE ⭐ 7/10

OTHER 📅 11 Dec 2025, 10:14 AM

Suven Life Sciences has achieved 100% patient enrollment for its Phase-2b clinical trial of Ropanicant, a treatment for Major Depressive Disorder, more than two months ahead of schedule. The trial successfully randomized 195 patients across 35 sites in the USA within just six months of initiation. Management expects the last patient to complete the study by February 2026, with topline efficacy and safety data anticipated in May 2026. This rapid enrollment reflects strong investigator interest and accelerates the timeline for a key clinical asset.

Reached 100% enrollment of 195 patients for Phase-2b Ropanicant trial in the USA.
Milestone achieved more than 2 months ahead of schedule and within 6 months of study initiation.
Last patient out (LPO) is projected for February 2026, with data readout in May 2026.
Trial evaluates efficacy via the Montgomery-Asberg Depression Rating Scale (MADRS) over 6 weeks.
Suven fully owns the intellectual property rights for Ropanicant (SUVN-911).

💡 Investors should monitor the stock closely leading up to the May 2026 data readout, as positive Phase-2b results would be a major valuation catalyst. However, remain aware of the high-risk nature of clinical-stage biotech investments until final efficacy is proven.

View All SUVEN Announcements on Live Market Tracking →

💰 Financial Performance

Revenue Growth by Segment

The NCE (New Chemical Entity) segment is currently in the research phase with negligible revenue; the US subsidiary Suven Neurosciences, Inc. reported total revenues of only INR 17.10 Lakhs for FY25. Historically, the consolidated entity (pre-demerger) had an operating income of INR 663.63 Cr in FY19, but the revenue-generating CRAMS business was moved to Suven Pharmaceuticals Ltd, leaving SUVEN with research-heavy, low-revenue operations.

Geographic Revenue Split

Revenue is primarily derived from international markets through its US-based subsidiary, Suven Neurosciences, Inc., which contributed INR 17.10 Lakhs in FY25. The company maintains assets in all major global markets to support its clinical trial pipeline.

Profitability Margins

Profitability is deeply negative due to high R&D intensity. Consolidated net loss after tax for the US subsidiary was INR 11,366.52 Lakhs in FY25. Standalone H1 FY26 loss before tax widened by 61.3% to INR 3,022.38 Lakhs from INR 1,873.78 Lakhs YoY, as the company has no significant commercial products to offset research costs.

EBITDA Margin

Core operating profitability is negative; consolidated operating loss before working capital changes worsened by 28.2% to INR 16,477.49 Lakhs in FY25 compared to INR 12,853.51 Lakhs in FY24. This reflects the high cash burn rate inherent in clinical-stage biopharmaceutical development.

Capital Expenditure

Standalone payments for the purchase of property, plant, and equipment (PPE) amounted to INR 213.74 Lakhs in H1 FY26, compared to INR 17.64 Lakhs in H1 FY25, representing a significant increase in infrastructure investment to support ongoing research activities.

Credit Rating & Borrowing

CRISIL has placed the company on 'Watch with developing implications' following the demerger. Historically, the company maintained a healthy financial profile with an interest coverage ratio of 44.13x in FY19, but current operations rely heavily on equity funding rather than debt, as evidenced by the INR 299.54 Cr raised through equity in H1 FY26.

⚙️ Operational Drivers

Raw Materials

Specific chemical reagents and active pharmaceutical ingredients (APIs) required for NCE development; while specific names are not listed, 'Cost of materials consumed' is a standard line item for their lab-scale manufacturing and clinical batch production.

Capacity Expansion

The company focuses on R&D capacity rather than industrial volume. Current focus is on advancing SUVN-502 through clinical trials. The company raised INR 299.54 Cr in H1 FY26 specifically to provide liquidity for these ongoing clinical obligations and research operations.

Raw Material Costs

Raw material costs are minimal compared to R&D and employee expenses; standalone cost of materials consumed is part of the broader R&D expenditure which drives the INR 160.75 Cr annual consolidated loss.

Manufacturing Efficiency

Not applicable as the company is in the clinical research stage; efficiency is measured by trial progression and patent filings rather than manufacturing throughput.

Logistics & Distribution

Not applicable for the current pre-commercial stage of their lead NCE products.

📈 Strategic Growth

Growth Strategy

Growth is predicated on the successful commercialization or out-licensing of NCEs like SUVN-502. The strategy involves securing external funding (INR 299.54 Cr raised recently) to complete Phase 2/3 trials and leveraging a 25% stake in Rising Pharma Holdings Inc. to create a pathway for generic drug assets.

Products & Services

New Chemical Entities (NCEs) for neurodegenerative disorders, specifically SUVN-502 for Alzheimer's disease and other forms of dementia.

Brand Portfolio

SUVEN, Suven Neurosciences.

New Products/Services

Lead candidate SUVN-502 is the primary focus for future revenue contribution; success in Alzheimer's trials would transition the company from pre-revenue to a high-growth biopharma player.

Market Expansion

Targeting major global markets for CNS (Central Nervous System) disorders, with a physical presence and subsidiary in the USA to manage clinical trials and regulatory filings.

Market Share & Ranking

Not disclosed for the NCE segment due to its developmental stage.

Strategic Alliances

Maintains a 25% stake in Rising Pharma Holdings Inc. (a joint venture with Shore Pharma Investments, LLC) to acquire and develop generic drug assets.

🌍 External Factors

Industry Trends

The biopharmaceutical industry is shifting toward specialized CNS treatments. While the sector is growing, it is characterized by high failure rates in clinical trials. Suven is positioned as a pure-play R&D house following its demerger from the revenue-stable CRAMS business.

Competitive Landscape

Competes with global big pharma and biotech firms developing Alzheimer's treatments; Suven's advantage lies in its specialized focus on neurodegenerative disorders.

Competitive Moat

The moat is based on intellectual property and patents for NCEs in major markets. This is sustainable only as long as patents are active and clinical data remains superior to emerging competitors.

Macro Economic Sensitivity

Highly sensitive to global economic conditions and the availability of venture/equity funding for biopharma, as the company requires continuous external capital to survive 5+ years of losses.

Consumer Behavior

Increasing global aging population is driving demand for dementia and Alzheimer's treatments, creating a massive potential patient base for successful NCEs.

Geopolitical Risks

Exposure to US regulatory changes (FDA) and trade policies, as the primary research and future market for their NCEs is the United States.

⚖️ Regulatory & Governance

Industry Regulations

Strict adherence to Ind AS financial reporting and clinical trial regulations set by the FDA (USA) and DCGI (India). The company is subject to the Companies Act, 2013, regarding internal financial controls.

Taxation Policy Impact

The company carries forward significant losses, resulting in deferred tax assets; however, recognition is subject to the probability of future taxable profits.

Legal Contingencies

The company identifies 'Contingencies' as a key area of management judgment, though specific pending court case values were not detailed in the provided snippets.

⚠️ Risk Analysis

Key Uncertainties

The 'Going Concern' assumption is the primary uncertainty; the company has incurred continuous losses for 5 years and is entirely dependent on the success of future fundraising and clinical trials.

Geographic Concentration Risk

High concentration in the USA for research operations and future revenue, with the US subsidiary holding assets of INR 1,776.28 Lakhs.

Third Party Dependencies

High dependency on collaborative partners for clinical trials and future commercialization; failure to retain key personnel or partners would halt operations.